Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | PPIA | P62937 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29935885 | 0.85 | CYP1A2 (0.55) | HPGDALDH1A1MAPTTSHRMEN1 | |
| SCHEMBL9156343 | 0.85 | CYP1A2 (0.55) | HPGDALDH1A1MAPTTSHRMEN1 | |
| SCHEMBL3558621 | 0.85 | P2RX7 (0.51) | RIPK1HPGDALDH1A1MAPTTSHR | |
| SCHEMBL2914008 | 0.83 | HPGD (0.65) | HPGDALDH1A1MAPTTSHRLMNA | |
| SCHEMBL3131049 | 0.83 | P2RX7 (0.56) | RIPK1HPGDALDH1A1MAPTTSHR | |
| Hydrochloric Acid SCHEMBL11157053 | 0.83 | CYP1A2 (0.53) | HPGDALDH1A1MAPTTSHRMEN1 | |
| SCHEMBL29941696 | 0.82 | RIPK1 (0.61) | RIPK1HPGDALDH1A1MAPTTSHR | |
| SCHEMBL1685923 | 0.82 | RIPK1 (0.61) | RIPK1HPGDALDH1A1MAPTTSHR | |
| SCHEMBL5527359 | 0.82 | ALDH1A1 (0.59) | RIPK1HPGDALDH1A1MAPTTSHR | |
| SCHEMBL19950428 | 0.82 | TSHR (0.42) | RIPK1HPGDALDH1A1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440710-B2 | HSL inhibitors useful in the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2013-05-14 | — | — | US | claimed |
| CN-102858743-A | Spiro-condensed cyclohexane derivatives as HSL inhibitors useful for the treatment of diabetes | HOFFMANN LA ROCHE | 2013-01-02 | — | — | CN | claimed |
| EP-2488493-A1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-08-22 | — | — | EP | claimed |
| WO-2011045292-A1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | WO | claimed |
| US-7166587-B2 | Carbamic acid alkyl ester derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-01-23 | — | — | US | claimed |
| US-20050075327-A1 | Carbamic acid alkyl ester derivatives | HOFFMAN-LA ROCHE INC. | 2005-04-07 | — | — | US | claimed |
| EP-4651949-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| WO-2024155834-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| EP-1673347-B1 | SUBSTITUTED DIBENZO-AZEPINE AND BENZO-DIAZEPINE DERIVATIVES USEFUL AS GAMMA-SECRETASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-08-19 | — | — | EP | disclosed |
| EP-2488493-B1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2015-04-15 | — | — | EP | disclosed |
| US-8440710-B2 | HSL inhibitors useful in the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2013-05-14 | — | — | US | disclosed |
| CN-102858743-A | Spiro-condensed cyclohexane derivatives as HSL inhibitors useful for the treatment of diabetes | HOFFMANN LA ROCHE | 2013-01-02 | — | — | CN | disclosed |
| EP-2488493-A1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011045292-A1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | WO | disclosed |
| US-7671072-B2 | Aminopyrazole derivatives as GSK-3 inhibitors | PFIZER INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | BENBOW JOHN W | 2007-11-29 | — | — | US | disclosed |
| US-7166587-B2 | Carbamic acid alkyl ester derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1673347-A1 | SUBSTITUTED DIBENZO-AZEPINE AND BENZO-DIAZEPINE DERIVATIVES USEFUL AS GAMMA-SECRETASE INHIBITORS | F. Hoffman-la Roche AG (CH) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040126-A1 | SUBSTITUTED DIBENZO-AZEPINE AND BENZO-DIAZEPINE DERIVATIVES USEFUL AS GAMMA-SECRETASE INHIBITORS | F. HOFFMAN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| US-20050075327-A1 | Carbamic acid alkyl ester derivatives | HOFFMAN-LA ROCHE INC. | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075327-A1 | Carbamic acid alkyl ester derivatives | BCHE, CHRM1, ADCY7 | RIPK1 3711/4885HPGD 4445/4885ALDH1A1 1434/4885 |
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | GSK3B, GSK3A, GSKIP | RIPK1 841/4885HPGD 2875/4885ALDH1A1 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.